Radcliffe & CardioNerds @AHA22: Reduction of Triglycerides With Pemafibrate

Published: 06 Nov 2022

  • Views:

    Views Icon 521
  • Likes:

    Heart Icon 0
Average (ratings)
No ratings
Your rating

AHA 22 - Dr Gurleen Kaur, Director of the CardioNerds Internship (Brigham and Women's Hospital, US) joins us in this collaboration between the @CardioNerds and Radcliffe Cardiology to interview Dr  Aruna Pradhan (Brigham and Women's Hospital, US), study director of the PROMINENT trial (NCT03071692) on the late-breaking data from AHA 2022. 

PROMINENT was a multicenter randomized trial aiming to determine whether pemafibrate (K-877) would delay cardiovascular events in diabetes patients. Patients received either two 0.2mg tablets of pemafibrate, or a placebo daily.

The study showed that pemafibrate was not associated with a reduction in adverse cardiovascular events. 

Access our full AHA 22 Scientific Coverage here.  

Recorded remotely from Boston, 2022.

Editors: Mirjam Boros and Jordan Rance
Videography: Mike Knight